SCHEDULE: FMR LLC Discloses 12.6% Stake in Avalo Therapeutics

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 12.6% in Avalo Therapeutics Inc. as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating a beneficial ownership of 2,879,481 shares of Avalo Therapeutics Inc. common stock.
• This ownership stake represents 12.6% of the class of securities.
• The filing is an amendment (Amendment No. 1) and the date of the event requiring the filing is March 31, 2026.
• FMR LLC is identified as a holding company (HC) and Abigail P. Johnson is identified as an individual investor (IN).
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a significant ownership stake by a major investor but does not provide new operational or financial information about Avalo Therapeutics Inc. itself.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, which can indicate confidence in the company's long-term prospects.
• The filing confirms that the ownership is for ordinary course of business, suggesting a passive investment rather than an activist stake.

Negatives

• The filing does not contain any negative financial or operational information about Avalo Therapeutics Inc. itself, as it is a disclosure of ownership by a third party.

Risks

• The filing does not explicitly mention any risks related to Avalo Therapeutics Inc. The primary risk associated with this type of filing is the potential for future changes in ownership or investment strategy by the reporting persons, which could impact the stock price.

Future Outlook

The filing itself is a disclosure of past ownership as of a specific date and does not contain forward-looking statements or guidance from Avalo Therapeutics Inc. The future outlook for Avalo Therapeutics Inc. would be found in their own financial reports.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares."
• "Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that significant filings like this Schedule 13G from major investment firms such as FMR LLC often signal sustained interest in a company's sector. Avalo Therapeutics operates in the biotechnology space, an industry characterized by high R&D investment and potential for significant growth or volatility based on clinical trial outcomes and regulatory approvals.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by FMR LLC may be viewed positively by some shareholders, indicating institutional confidence. However, it also means a large portion of shares are held by a single entity, which could influence market dynamics.
• Management of Avalo Therapeutics Inc.: The presence of a large institutional holder like FMR LLC can bring increased scrutiny and potentially influence corporate governance decisions.
• Potential Investors: This filing may attract attention from other investors interested in companies with significant institutional backing.

Next Steps

• Monitor future filings from FMR LLC and Abigail P. Johnson for any changes in their ownership stake in Avalo Therapeutics Inc.
• Review Avalo Therapeutics Inc.'s own financial reports and press releases for operational updates and strategic developments.

Key Dates

Keywords

Schedule 13G, FMR LLC, Abigail P. Johnson, Avalo Therapeutics Inc., Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Investment